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ScienceDirectNeurodegenerative and other protein misfolding diseases are
associated with the aggregation of a protein, which may be
mutated in genetic forms of disease, or the wild type form in late
onset sporadic disease. A wide variety of proteins and peptides
can be involved, with aggregation originating from a natively
folded or a natively unstructured species. Large deposits of
amyloid fibrils are typically associated with cell death in late
stage pathology. In this review, we illustrate the contributions of
cryo-EM and related methods to the structure determination of
amyloid fibrils extracted post mortem from patient brains or
formed in vitro. We also discuss cell models of protein
aggregation and the contributions of electron tomography to
understanding the cellular context of aggregation.
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Introduction: amyloid diseases
An alternative fold of polypeptides that is not strongly
coupled to amino acid sequence violates the general notion
that a unique, stable three-dimensional (3D) structure is
associated with each gene sequence encoding a protein.
Moreover, this alternate fold, the cross-b structure, is
strongly associated with invariably fatal degenerative dis-
eases, for which there are few diagnostic tools and hardly any
treatments [1]. A wide variety of different peptides and
proteins can be converted into fibrils containing long ribbons
of cross-b structure, generally known as amyloid fibrils.
Alzheimer’s disease (AD) is the commonest form of
dementia, the progressive decline of cognitive processes
that affects about 20% of people over 75. Extracellular
plaques of the Amyloid-b (Ab) peptide and intraneuronal
tangles of hyperphosphorylated tau protein (a microtubuleCurrent Opinion in Structural Biology 2019, 58:34–42 associated protein) in the brains of AD patients are associ-
ated with neuronal death and loss of cholinergic pathways
[2]. AD is not usually inherited, but some genetic factors
predispose individuals to the disease and lower the age of
onset. Most of the genes known to be involved play a role in
the metabolism of APP (b-amyloid precursor protein), a
transmembrane protein which is cleaved by proteases
termed secretases to release the Ab peptide. Ab is normally
40 residues long, but abnormal cleavage produces Ab 1–42,
which has a strong tendency to form amyloid.
The next most common neurodegenerative disease is
Parkinson’s (PD). PD and the related Lewy body disease,
which accounts for about 20% of dementia cases, cause
movement abnormalities and dementia. Lewy bodies are
intracellular deposits of the protein a-synuclein, a highly
conserved synaptic protein (named for both synaptic and
nuclear localization) that plays a role in synaptic vesicle
recycling [3]. The most conserved region of the protein is
predicted to form an amphipathic helix, consistent with a
role in binding lipids or vesicles [4].
A group of severe neurodegenerative diseases with a clear
genetic cause, including Huntington’s disease (HD), arise
from expansion of glutamine repeats (CAG codon), and are
known as CAG repeat diseases. The protein huntingtin
(>3000 residues, with long stretches of glutamine and also
proline repeats near the N terminus), essential for embry-
onic neural development, is found in intranuclear and
cytoplasmic deposits of degenerating neurons [5]. The
repeat region is in exon 1 of the protein, and the aggregates
contain significant amounts of isolated exon 1. Individuals
with less than 37–42 repeated glutamines do not develop
the disease, but those with over 42 glutamines do, in
correlation with its in vitro aggregation into amyloid-like
fibrils and ribbons. The longer the repeat, the earlier the
disease onset, and the more aggregation prone the protein.
A single particle cryo-EM structure revealed the fold of
soluble, full length huntingtin, which consists largely of
HEAT repeats, but does not contain density for exon1,
owing to disorder [6].
The prion diseases (transmissible spongiform encepha-
lopathies) are the only amyloid diseases that have been
clearly demonstrated to be transmissible. Ritual canni-
balism formerly practiced by the Fore people of New
Guinea spread the fatal disease kuru through the popula-
tion. Creutzfeld Jacob disease (CJD) has been transmit-
ted to patients receiving human growth hormone, and
about 200 people died of variant CJD, derived from mad
cow disease, itself propagated in cows via contaminated
feed in the 1980s. The prion protein Prp is a brainwww.sciencedirect.com
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play a role (so far unknown) in synaptic function. In its
normal (cellular) form, PrpC, it has a mainly a-helical
structure. The b-sheet containing PrpSC (the scrapie
form, named after the original ovine disease) from
diseased brain can induce PrpC in previously healthy
individuals to convert to the scrapie form through an
unknown mechanism. Consistent with the clear link
between the amyloid forming protein and disease, Prp
knockout mice are not susceptible to infection. Differ-
ent strain types can be detected by different glycosyla-
tion patterns, and these are propagated in experimental
animals [7].
There are many major, unanswered questions about
amyloid disease. Although pathology always involves cell
death, related to aggregation of the protein(s) involved,
the toxic species, whether fibril fragments, assembly
intermediates or products, remain unknown, as do their
precise mechanisms of inducing toxicity. In prion disease,
the infectious species responsible for transmission of the
prion conformation is distinct from the species causing
toxicity, which begins to develop only after the infectivity
has reached its maximum level [7]. In general, fibril
structures extracted from patient brain differ from those
grown in vitro from the same precursor protein, but the
structural differences have not so far provided an expla-
nation for the pathology. In addition, the tissue specificity
and delayed onset characteristic of each disease variant
are not understood. In the case of intrinsically disordered
proteins, hints of physiological function are emerging,
through reversible liquid–liquid phase separation provid-
ing a protective environment to shield the less stable
proteins from temporary stress. But at least in some cases,
the liquid phase can progress to irreversible fibrillar
aggregates.
Amyloid fibril structure and assembly
Aggregation often occurs after exposure of the monomer
to denaturing conditions and low pH, and requires partial
or total unfolding of the native structure to allow the
formation of intermolecular b-sheets. Mutations that
destabilise the native fold can favour the conformational
conversion. Despite the great variety in length, composi-
tion and sequence of proteins and peptides capable of
forming amyloid aggregates, the resulting fibrils are char-
acterized by their archetypal all-b tertiary structure that is
a common feature of protein molecules in the amyloid
state [8–10]. Their common core structure is the cross-b
fold, shown in the first panel of Figure 1, in which
b-strands form long ribbon-like sheets that pack against
each other to form long protofilaments that assemble
together into fibrils. They share a cross-b X-ray diffraction
pattern arising from the 4.8 A˚ b-strand spacing and the
10 A˚ inter-sheet spacing. They have a filamentous
morphology, and bind thioflavin-T (ThT), Congo red
and other amyloidophilic compounds [11,12]. Given thatwww.sciencedirect.com the accumulation of protein aggregates is a common
characteristic of many clinically, genetically and patho-
logically distinct neurodegenerative diseases, determin-
ing the atomic structures of these fibrous aggregates,
which are strongly associated with selective neurodegen-
eration, is likely to be important in understanding their
formation, spreading and clearance in the human body.
Until recently, few amyloid structures were determined
at high resolution. Recent advances in solid state NMR
[13,14] and particularly in cryo-EM [15] have generated
substantial advances in structural information. A key
element has been the dramatic improvement in resolu-
tion achievable by single particle cryo-EM, because of its
power in dealing with heterogeneous assemblies. Amy-
loid fibrils are typically variable in protofilament struc-
ture, packing and in long range helical twist. Such varia-
tions limit the resolution achievable by solution methods
that average the fibril structures present in the sample.
However, single particle cryo-EM can be used to com-
putationally extract short segments of the fibrils and to
classify them into structurally homogeneous subsets (e.g.
Ref. [16]). With current electron detectors and software,
this approach has yielded a series of near atomic struc-
tures revealing the subunit fold in fibrils of physiologi-
cally relevant amyloid proteins including yeast prions
[17], a-synuclein [18], Ab42 [19] and tau, the latter
extracted from post mortem human brain (Figure 1).
These structures have made clear that specific conformers
of a protein molecule manifest in diseased tissue, as the
folds of the tau filament core for paired helical and straight
filaments in AD [15] (Figure 1) are significantly differ-
ent from its fold in Pick’s disease [20]. As mentioned,
structures derived from fibrils produced in vitro often
differ those that form in the brain; for example, infectious
mammalian PrP fibrils extracted from mice have been
characterized using negative stain EM and found to adopt
a short, paired double helical structure, distinct from in
vitro formed fibrils [21].
Collectively, these reports reveal a great variety of cross-b
molecular folds [22], as well as polymorphism in subunit
structure and packing interfaces [15,20,23]. Specific
folds are likely to be influenced by the environment in
which the aggregates are formed. Indeed, the in vitro
aggregation kinetics depend strongly on environmental
conditions, such as the presence of the corresponding seed
fibrils [24,25] or lipid vesicles [26]. Moreover, the interface
between protofilaments has been proven variable for dis-
ease-specific conformers, which may provide a molecular
basis for the emergence of fibril strains (Figure 1). This is
particularly evident for paired versus straight helical fila-
ments of tau in AD [15] (Figure 1).
b-strand stacking and sequence specificity
In general, fibrils tend to adopt a parallel, in-register
arrangement of their constituent b-strands [27]. ThisCurrent Opinion in Structural Biology 2019, 58:34–42
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Cross-b structure and tau deposits in Alzheimer’s disease brain. From left to right, the upper panels show a schematic of the b-strand
arrangement in the cross-b core of an amyloid fibril; the AD brain used for cryo-EM; and a Thioflavin-S stained light microscopy image showing
abundant neurofibrillary tangles in temporal cortex. Lower panels, an electron micrograph of negatively stained filaments with a blue arrow
indicating a paired helical filament (PHF) and a green arrow indicating a straight filament (SF); cryo-EM reconstructions of PHFs (blue) and SFs
(green) with detailed cross sections; and de novo atomic models of filaments showing C-shaped subunits stacked to form each protofilament, with
protofilaments paired into twisted polymorphic fibrils (Tau panels adapted from Ref. [15]).may be because antiparallel b-strands have an intrinsic
limit on b-strand length ([28] and that parallel b-sheets
tend to contain more b-strands than antiparallel b-sheets
[29], making in-register parallel b-strand stacking of
identical residues more suitable for templated amyloid
fibril growth [30]. However, little consensus is evident
among the atomic models of the few filament cores that
have been solved to date, raising the question as to how
and why a protein adopts a specific fold within the
amyloid state in different pathologies.
The two all-b structural motifs most closely associated
with amyloid and prion structure are cross-b packing [31]
and b-helices [17] respectively (Figure 2). The generic
cross-b structure, widely accessible to peptides and pro-
teins of varying lengths with unrelated amino acidCurrent Opinion in Structural Biology 2019, 58:34–42 sequences, is a polypeptide scaffold characterized by arrays
of continuous b-sheets, separated by an inter-sheet distance
of 8–12 A˚, running parallel to the long axis of the fibrils
(Figure 2a). The importance of sequence-independent
hydrogen bonding in defining the cross-b fold is underscored
by the observation that polar, non-polar and even homopol-
ymeric sequences of amino acids can form cross-b amyloid
fibrils [32].
By contrast, b-helices, and in particular b-solenoids, are
intricate structures composed of three b-sheets arranged
in a triangular fashion, mediated by specific interactions
not accessible to most amino acid sequences [33]
(Figure 2b). A 21 amino acid sequence capable of forming
a four amino acid b-strand, a two-residue b-arc, a five
amino acid b-strand, a two-residue or three-residue b-arc,www.sciencedirect.com
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Atomic structures of amyloid fibrils, viewed down the fibril axis. (a) The cross-b structure, (b) b-helices, (c) a combination of cross-b and b-helical
structural motifs. (a) cross-b packing between laminated b-sheets is generic and can be formed by any amino acid sequence (open circles
denoting any sidechain). Overlay of the backbones of cross-b structures from Alzheimer’s disease tau filaments [15], Pick’s disease tau filaments
[20] and fibrils formed by a peptide fragment [13] all overlap better than 1.5 A˚ rmsd. (b) b-helices require a specific pattern of hydrophobic
residues (green-filled circles) on the inside, polar residues (blue-filled circles) on the outside, and a pivotal b-arch-forming glycine (pink-filled circle)
closing the triangular motif. Overlay of the backbones of the b-helix in Alzheimer’s disease tau filaments and HET-s b-helices formed by the [HET-
s] prion [17] agree within 1.3 A˚ rmsd. (c) Schematic view of the C-shaped protofilament core formed by the tau protein in human Alzheimer’s
disease brain. Each C consists of a b-helix region, where three b-sheets are arranged in a triangular fashion, and two regions with a cross-b
architecture, where pairs of b-sheets pack anti-parallel to each other [15].and a six amino acid b-strand all closed by a 70 glycine
conformation is likely to have the following polar (P) /
nonpolar (H) periodicity: HPH/PPHPPHPHPPPHPHH/
PHGPH/P. Such hydrophobic patterning, with the occur-
rence of a glycine residue at position 19, is non-universal,
requiring specific packing of side-chains (Figure 2b).
The tight regulation of b-helices by geometric and amino
acid sequence restraints that do not constrain generic cross-
b arrangements implies that these two all-b structural
motifs display different behaviours. While cross-b packing
(Figure 2a) is largely unaffected by point mutation, which
typically only alters the kinetics of cross-b fibril formation
[34], the mutation of the universally conserved b-arch-
forming glycine (Figure 2b) to alanine is sufficient to
disrupt the formation of the b-helix, preventing seeding
and infectivity of the [Het-s] prion of the filamentous
fungus Podospora anserina [35]. The sequence-indepen-
dent nature of cross-b filament formation [32] makes it
more widely accessible to many peptides and proteins than
the sidechain specificity of b-helical assembly. The pro-
miscuity of the cross-b fold allows this structural scaffold to
template dissimilar protein molecules and cross-seed, mak-
ing amino acid sequences that are more than 70% identical
highly prone to coaggregation [36].www.sciencedirect.com Both sidechain-specific b-helical and generic cross-b
structural elements are present in the tau protofilament
formed in human AD brains (Figure 2c). The core of the
paired helical filaments and straight filaments (Figure 1)
are composed of eight b-sheets that run along the length
of the protofilament, adopting a C-shaped architecture
(Figure 2c). Each C consists of a b-helix region with three
b-sheets are arranged in a triangular fashion, and two
regions with a cross-b architecture characterized by pairs
of b-sheets that pack anti-parallel to each other
(Figure 2c). This C-shaped protofilament forms the build-
ing block for two fibril polymorphs, akin to prion strains,
called paired helical filaments and straight filaments
(Figure 1). Significant differences in the lateral contacts
formed between two of the common protofilament struc-
tures give rise to the ultrastructural polymorphism [37]
displayed by tau filaments in AD (Figure 1).
Importantly, the tau protofilament in human Pick’s dis-
ease brains adopts a different fold, despite having many
b-structure residues in common with the AD tau proto-
filament, only containing generic cross-b structural ele-
ments [20]. The discovery that tau residues 337–357 can
adopt both a canonical b-helix structure in an Alzheimer’s
disease brain and cross-b packing in Pick’s diseaseCurrent Opinion in Structural Biology 2019, 58:34–42
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disease-specific folds in the ordered cores of tau filaments.
It is clear that a combination of molecular and assembly
polymorphism is responsible for the conformational
diversity of fibril polymorphs across all proteinopathies.
Different amyloid fibril polymorphs have distinct physi-
cal properties, such as surface hydrophobicity [13], kinet-
ics of self-assembly [39], reversibility [40], and thermo-
dynamic stability [41]. Thus, the sequential, structural
and physical determinants of fibril polymorphs lead to a
variety of behaviours in vivo, possibly resulting in a broad
spectrum of disease phenotypes [42].
Amyloid aggregation in cells
Protein aggregation into amyloid fibrils has been exten-
sively studied by biophysical experiments in vitro. Fibril
formation begins with a slow nucleation phase, followed by
fibril elongation, and is greatly accelerated by seeding with
preformed fragments. In the physiological setting, how-
ever, many factors modify the course and outcome of
aggregation, notably the protein quality control machinery
for fibril fragmentation and disaggregation [43]. DepositionFigure 3
Aggregation pathway of Huntingtin exon 1 in cells and in vitro. (a) Huntingti
liquid phase droplets to irreversible fibrous aggregates in a HEK293 cell (rep
conversion, showing the start and end points of conversion from liquid drop
the original droplets [48]. The in vitro experiment was done with 25Q, with 
aggregation occurs too rapidly to follow with pathogenic glutamine repeat le
Current Opinion in Structural Biology 2019, 58:34–42 of aggregates in cells can take many forms, and is typically
characterised by the observation of fluorescent foci. EM of
these structures reveals a wide range of assemblies, inter-
acting in different ways with other cellular components.
An emerging physiological pathway for
protein segregation
In budding yeast, the [PSI+] prion forming protein,
sup35, consists of a folded, translation termination factor
preceded by a low complexity N-terminal, prion domain
and a charged, unstructured middle domain. A recent
study shows that stress conditions such as low pH trigger
liquid phase separation driven by the prion domain,
which reversibly recruits the molecule into liquid dro-
plets. After the stress is relieved, it is released into its
viable form [44]. Deletion of the prion domain results
in irreversible aggregation of the folded domain upon
stress. Another recent study, in a mammalian system,
shows that reversible aggregation of the RNA-binding
protein TDP-43 functions in muscle regeneration [45].
With the findings of physiological roles for liquid phase
separation, the first hints are beginning to emerge about(a) (b)
0.0 min
52.2 min
(c)
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n exon 1 aggregates (43Q) in the course of conversion from reversible,
roduced from Ref. [48]). (b,c) The in vitro counterpart of this
lets to fibrous outgrowth, which consumes all the fluorescence from
its phase separation induced by addition of dextran, because
ngths.
www.sciencedirect.com
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retained in evolution. However, adaptive phase separa-
tion may come at a cost, as liquid like compartments may
have the capacity to convert to irreversible solids or
promote amyloid aggregation in disease. Several proteins
are known to phase separate into liquid like assemblies
that mature into solid aggregates in vitro, particularly
when the proteins carry disease associated mutations
[46,47]. In the case of Huntingtin exon1 in vitro and
as expressed in mammalian and yeast models, the pro-
tein can separate into a reversible liquid phase,
which promotes its conversion into irreversible amyloid
aggregates (Figure 3) [48].
Interactions of aggregating species with
cellular components
A model of [PSI+] prion formation and transmission, in
which the translation terminal factor domain is replaced
by YFP and the fluorescent construct overexpressed, shows
a regimented arrangement of short bundles of fibrils [49].
Modulation of the Hsp70 chaperone network revealed that
the disaggregation systems of Hsp104, a AAA+ protein
involved in extraction of proteins from large aggregates,
and Hsp110, a nucleotide exchange factor for Hsp70 that
confers disaggregation activity on the Hsp70 system, are
both involved in determining the structure of the prion
deposits. Hsp104 is required for [PSI+] propagation, but
its overexpression converts the fibrils into amorphous,
but still irreversible, aggregates. The level of Hsp110
appears to set the fibril length. In vivo, amyloid fibrils tend
to be much shorter than the ones grown in vitro, likely due to
the actions of the chaperone systems.Figure 4
(a)
Huntingtin aggregates in a cell model. (a) Tomogram section and (b) corres
1 aggregate from a FIB-milled lamella of a Hela cell (reproduced from Ref. [
bar, 400 nm.
www.sciencedirect.com Cryo electron tomography (ET) explores the nanostruc-
tures of fibrillar deposits and their interactions with other
components in cells. The difficulty is to gain access to the
appropriate cellular regions—the aggregates tend to be in
the thicker parts of cells, and some form of sectioning is
needed to produce layers of vitrified cell structure con-
taining the aggregates but thin enough for transmission
EM, that is, well under a micron in thickness. Cryo-
sectioning provides a view of the structures in very thin
sections (e.g. Ref. [49]) but it is mechanically damaging
and restricts the section thickness to little more than
50 nm, giving a very limited window into the cell.
Although it is useful for correlative fluorescence and
EM, and for verifying features seen by the easier method
of freeze substitution (see Stahlberg chapter), it does not
provide an undistorted, high resolution view of cell struc-
ture. Focussed ion beam (FIB) milling offers a way to
produce relatively undisturbed layers of suitable thick-
ness for electron tomography, and two recent studies
show Huntingtin exon 1 and poly GA aggregates in
mammalian cell models by cryo-ET of FIB milled cells
[50,51]. The huntingtin inclusions consist of jumbled,
short fibrils in either nuclear or cytoplasmic aggregates. In
the cytoplasm, there is ER recruited around the edges of
the inclusions, interacting with fibril ends and distorted in
a way similar to that previously reported with vesicles and
short amyloid fibrils in vitro (Figure 4) [52]. In the case of
poly GA, a Gly-Ala repeat found in an amyloidogenic
protein in ALS and frontotemporal dementia, irregular
twisted fibrils interact with and appear to stall protea-
somes [51]. These studies suggest mechanisms by which
the aggregates might cause damage to cells, but the initial
causes of pathology and damage remain obscure.(b)
Current Opinion in Structural Biology
ponding rendered view of a cryo-tomogram of a Huntingtin exon
50]). Fibrils, blue; ribosomes, green, ER, red; vesicles, white. Scale
Current Opinion in Structural Biology 2019, 58:34–42
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system
In bacteria, yeast and plants, the AAA+ Hsp100 chaper-
ones cooperate with the Hsp70 system to extract protein
from aggregates or from prion fibrils, and return them to
the unfolded state. This activity involves threading of the
protein chain through the unfoldase/disaggregase Hsp104
or ClpB in yeast or bacteria respectively. However, the
Hsp100 family is not found in the cytosol of metazoa.
Disaggregase activity is provided by the Hsp70 system
itself, with specific forms of the Hsp40 and Hsp110
partner proteins. It has been demonstrated for two in
vitro amyloid systems, a-synuclein and Huntingtin exon
1, that a specific combination of Hsp70-40-110 compo-
nents can depolymerise the fibrils and return the subunits
into solution as monomers [53,54]. In vivo studies have
demonstrated that fibril deposition is inversely related to
the cellular levels of these chaperones [43].
Concluding remarks
In summary, recent advances in single-particle cryo-EM
have enabled the structure determination of amyloid
fibrils from post-mortem human brain tissue. These find-
ings demonstrate that cryo-EM allows near-atomic char-
acterization of amyloid filaments from patient-derived
material, paving the way for the investigation of a range
of human pathologies. Current evidence suggests that
each neurodegenerative disease has its own unique amy-
loid fibril structural signature that can be recognized by
cryo-EM. As more clinically derived structures emerge,
we should begin to understand the hypothesized link
between protein aggregates and clinical phenotype,
enabling a targeted approach to structure-based drug
design and the development of biomarkers for early
detection of diseases. In the physiological context, elec-
tron tomography can provide high resolution structural
information within intact regions of cells to investigate
the interplay between amyloid assemblies and other
cellular components.
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